Collegium Pharmaceutical (NASDAQ:COLL) Posts Quarterly Earnings Results, Misses Estimates By $0.16 EPS

Collegium Pharmaceutical (NASDAQ:COLL) announced its earnings results on Thursday. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, missing the consensus estimate of $2.20 by ($0.16), FiscalAI reports. The business had revenue of $205.45 million for the quarter, compared to the consensus estimate of $206.36 million. Collegium Pharmaceutical had a net margin of 7.72% and a return on equity of 102.03%. Collegium Pharmaceutical’s revenue for the quarter was up 12.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.77 EPS.

Here are the key takeaways from Collegium Pharmaceutical’s conference call:

• Collegium reported record 2025 results with $780.6M in net revenues (up 24%), a record $460.5M adjusted EBITDA (up 15%), $329.3M cash from operations and ended the year with $386.7M in cash while reducing net leverage to below 1x.
• Jornay PM accelerated growth (prescriptions +20% y/y, $148.9M revenue, +48% pro forma), grew prescribers to ~29,000 after expanding the sales force to ~180 reps, and is guided to $190–$200M in 2026 ( >30% growth).
• The core pain portfolio remains a durable cash generator (2025 pain revenues ~$631.7M, +6% y/y) and Collegium struck an authorized‑generic agreement with Hikma for the Nucynta franchise (Hikma launched Nucynta and Nucynta ER is expected Q1 2026) with a profit‑share structure the company says will mitigate LOE impact.
• Management strengthened financial flexibility by closing a $980M syndicated credit facility that lowers interest costs and funds business development, and returned capital via a $25M repurchase while retaining $150M of repurchase capacity.

Collegium Pharmaceutical Price Performance

Collegium Pharmaceutical stock traded down $2.41 on Friday, reaching $41.82. The company’s stock had a trading volume of 243,178 shares, compared to its average volume of 414,376. Collegium Pharmaceutical has a twelve month low of $23.23 and a twelve month high of $50.79. The company has a market cap of $1.32 billion, a price-to-earnings ratio of 25.91 and a beta of 0.64. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.27 and a current ratio of 1.36. The business’s fifty day moving average price is $46.65 and its 200 day moving average price is $42.00.

Trending Headlines about Collegium Pharmaceutical

Here are the key news stories impacting Collegium Pharmaceutical this week:

• Positive Sentiment: Reported record full‑year net revenues of $780.6M (up 24% YoY) and Q4 net revenues of $205.4M (up 13% YoY), showing topline growth that supports management’s growth narrative. Collegium Reports Fourth Quarter and Full-Year 2025 Financial Results
• Positive Sentiment: Company expects strong Jornay PM momentum — management is targeting ~31% Jornay revenue growth for 2026 and emphasized advancing the pain portfolio, which supports medium‑term revenue upside if execution continues. Collegium targets 31% Jornay revenue growth for 2026 while advancing pain portfolio durability
• Positive Sentiment: ESG / community engagement: a new partnership with Boston Legacy FC highlights sensory‑inclusion initiatives — positive for brand/ESG narrative but unlikely to move near‑term fundamentals. Collegium Partnership With Boston Legacy FC Backs Sensory Inclusion And ESG Story
• Neutral Sentiment: Analyst activity is mixed: Needham trimmed its price target from $56 to $54 but kept a Buy — this reduces upside slightly but preserves institutional confidence. Benzinga
• Neutral Sentiment: Broad analyst coverage and commentary pieces summarizing the quarter and outlook may add short‑term volatility as investors parse guidance and product dynamics. Deep Dive Into Collegium Pharmaceutical Stock: Analyst Perspectives (5 Ratings)
• Negative Sentiment: Q4 EPS missed consensus (reported $2.04 vs. ~$2.20 expected) and revenue narrowly missed estimates — the earnings shortfall is the primary immediate negative catalyst. Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Miss Estimates
• Negative Sentiment: FY26 revenue guidance ($805M–$825M) is roughly in line with consensus but EPS guidance was not clearly reaffirmed in filings/calls, leaving uncertainty on margin trajectory and near‑term profitability. Call/transcript coverage highlights investor questions about margins and product durability. Collegium Pharmaceutical, Inc. Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Short‑interest data in feeds shows anomalous/zero values for February; treat short‑interest signals as unreliable until corrected.

Insider Buying and Selling

In other news, EVP Scott Dreyer sold 17,600 shares of Collegium Pharmaceutical stock in a transaction on Monday, December 8th. The stock was sold at an average price of $48.17, for a total value of $847,792.00. Following the completion of the sale, the executive vice president directly owned 103,613 shares of the company’s stock, valued at approximately $4,991,038.21. This trade represents a 14.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Rita J. Balice-Gordon sold 3,650 shares of the business’s stock in a transaction on Friday, December 5th. The stock was sold at an average price of $47.03, for a total value of $171,659.50. Following the sale, the director owned 52,629 shares of the company’s stock, valued at approximately $2,475,141.87. The trade was a 6.49% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 2.51% of the company’s stock.

Institutional Trading of Collegium Pharmaceutical

Several institutional investors and hedge funds have recently added to or reduced their stakes in COLL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Collegium Pharmaceutical by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,046 shares of the specialty pharmaceutical company’s stock valued at $569,000 after purchasing an additional 825 shares during the last quarter. Millennium Management LLC grew its holdings in Collegium Pharmaceutical by 248.5% during the 1st quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock worth $19,338,000 after acquiring an additional 461,914 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Collegium Pharmaceutical by 7.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,014 shares of the specialty pharmaceutical company’s stock valued at $2,120,000 after acquiring an additional 4,625 shares during the last quarter. Jane Street Group LLC lifted its stake in shares of Collegium Pharmaceutical by 218.7% in the 1st quarter. Jane Street Group LLC now owns 131,520 shares of the specialty pharmaceutical company’s stock valued at $3,926,000 after purchasing an additional 90,255 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in shares of Collegium Pharmaceutical by 3.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 72,068 shares of the specialty pharmaceutical company’s stock worth $2,131,000 after purchasing an additional 2,592 shares during the last quarter.

Analysts Set New Price Targets

COLL has been the topic of several research analyst reports. Zacks Research downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Barclays dropped their price objective on shares of Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating on the stock in a report on Friday, January 9th. Wall Street Zen raised Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. HC Wainwright restated a “buy” rating and set a $60.00 price target (up from $46.00) on shares of Collegium Pharmaceutical in a research note on Friday, January 9th. Finally, Truist Financial set a $58.00 price objective on Collegium Pharmaceutical in a research report on Tuesday, February 10th. Five research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $53.00.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.